Loading clinical trials...
Loading clinical trials...
A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment
Conditions
Interventions
selumetinib
Locations
3
Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Department of Oncology, National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Start Date
September 1, 2014
Primary Completion Date
March 8, 2018
Completion Date
March 8, 2018
Last Updated
July 10, 2018
NCT06305754
NCT05920356
NCT06128551
NCT07251582
NCT01720836
NCT06567015
Lead Sponsor
National Taiwan University Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions